Abstract
Context and objectives
The impact of complementary and integrative medicine (CIM) on adherence to chemotherapy regimens is unclear. We explored the effect of patient-tailored CIM treatments on the relative dose intensity (RDI) of chemotherapy among patients with breast and gynecological cancer.
Methods
Chemotherapy-treated patients with breast or gynecological cancer were referred by their oncology healthcare professional to a CIM treatment program. Adherence to integrative care (AIC) was defined as ≥4 CIM treatments, with ≤30 days between each treatment. Relative dose intensity (RDI) of chemotherapy was compared between CIM-treated patients and controls, and among adherence sub-groups.
Results
RDI was calculated for 106-treated patients (62 AIC) and 75 controls. Baseline-to-6-week RDI values were similar in both study arms, with a lower % RDI <1.0 among controls at 12 weeks (47 vs. 57.5%; P = 0.036). Adherence sub-groups had similar RDI values, though at 6 weeks, the AIC group had lower % RDI <1.0 (33.9 vs. 54.5%, P = 0.046). Total administered medication dose/planned dose was higher in the AIC group at 6 weeks for paclitaxel (82%/50%, P = 0.025) and carboplatin (87%/67%, P = 0.028), with no difference in cytoxan/adriamycin dosages.
Conclusion
A patient-tailored CIM program for patients with breast or gynecological cancer may be associated with a lower percentage of reduced RDI at 6 weeks, this in a sub-group of patients with higher adherence to CIM, and for specific chemotherapy agents, though this benefit did not persist after 12 weeks. Further research is needed to better understand the impact of CIM in cancer care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aaronson N, Ahmedzai S, Bergman B, Bullinger M et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
Ben-Arye E, Schiff E, Shapira C, Frenkel M, Shalom T, Steiner M (2012) Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns 89(3):423–429
Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511
Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K (1991) The edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9
Chirivella I, Bermejo B, Insa A, Pérez-Fidalgo A, Magro A, Rosello S, García-Garre E, Martín P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114(3):479–484
Ell K, Vourlekis B, Xie B, Nedjat-Haiem FR, Lee PJ, Muderspach L, Russell C, Palinkas LA (2009) Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer 115(19):4606–4615
Green JA, Dawson AA, Fell LF, Murray S (1980) Measurement of drug dosage intensity in MVPP therapy in Hodgkin’s disease. Br J Clin Pharmacol 9:511–514
Greer JA, Pirl WF, Park ER, Lynch TJ, Temel JS (2008) Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res 65(6):549–552
Griggs JJ, Culakova E, Sorbero ME, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH (2007) Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25(3):277–284
Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281–1288
Keshet Y, Schiff E, Samuels N, Ben-Arye E (2015) Giving voice to cancer patients: assessing non-specific effects of an integrative oncology therapeutic program via short patient narratives. Psychooncology. 24(2):169–174
Lenhart C (2005) Relative dose intensity: improving cancer treatment and outcomes. Oncol Nurs Forum 32(4):757–764
Lesi G, Razzini G, Musti MA, Stivanello E, Petrucci C, Benedetti B, Rondini E, Ligabue MB, Scaltriti L, Botti A, Artioli F, Mancuso P, Cardini F, Pandolfi P (2016) acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcCliMaT). J Clin Oncol 34(15):1795–1802
Ottevanger PB, De Mulder PH, Grol RP et al (2002) Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice. Anticancer Res 22:459–465
Shalom-Sharabi I, Samuels N, Lavie O, Lev E, Keinan-Boker L, Schiff E, Ben-Arye E (2017) Effect of a patient-tailored integrative medicine program on gastro-intestinal concerns and quality of life in patients with breast and gynecologic cancer. J Cancer Res Clin Oncol 43(7):1243–1254
Shayne M, Crawford J, Dale DC, Culakova E (2006) Lyman GH; ANC Study Group. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 100(3):255–262
Vavra KL, Saadeh CE, Rosen AL, Uptigrove CE, Srkalovic G (2013) Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center. J Oncol Pract. 9(5):e203–e211
Weeks LC, Seely D, Balneaves LG, Boon HS, Leis A, Oneschuk D, Sagar SM, Verhoef MJ (2013) Canadian integrative oncology research priorities: results of a consensus-building process. Curr Oncol. 20(4):e289–e299
Weycker D, Barron R, Edelsberg J, Kartashov A, Lyman GH (2012) Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat 133(1):301–310
Wildiers H, Reiser M (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77(3):221–240
Acknowledgements
We thank Ms. Ronit Leiba for her assistance in the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was not funded by any source.
Conflict of interest
Ilanit Shalom-Sharabi declares that she has no conflict of interest. Noah Samuels declares that he has no conflict of interest. Ofer Lavie declares that he has no conflict of interest. Efraim Lev declares that he has no conflict of interest. Lital Keinan-Boker declares that she has no conflict of interest. Eran Ben-Arye declares that he has no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Research involving human and animals rights
This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Shalom-Sharabi, I., Lavie, O., Samuels, N. et al. Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting. J Cancer Res Clin Oncol 143, 2535–2543 (2017). https://doi.org/10.1007/s00432-017-2509-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-017-2509-0